Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  leuprolide acetate
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-25 of 32 for your search:
Start Over
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive Breast Cancer Patients
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: RenJiH-BC-002, NCT02221999
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CALGB 90203, U10CA031946, CDR0000526353, NCT00430183
Radiation Therapy and Androgen Deprivation Therapy in Treating Patients Who Have Undergone Surgery for Prostate Cancer (RADICALS)
Phase: Phase III
Type: Treatment
Status: Active
Age: Any age
Sponsor: Other
Protocol IDs: CDR0000571528, MRC-RADICALS-PR10, ISRCTN40814031, EUDRACT-2006-000205-34, EU-20767, PR13, NCT00541047
Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG 0815, CDR0000648194, NCI-2011-01948, NCT00936390
Androgen-Deprivation Therapy and Radiation Therapy in Treating Patients With Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: RTOG-0924, CDR0000701128, NCI-2011-02674, NCT01368588
Hypo-fractionated Proton Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GU003-10, NCT01492972
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: S1216, SWOG-S1216, NCI-2012-02876, NCT01809691
A Study of the Effect of Enantone LP 11.25 mg (Leuprorelin) on the Histological Progression of Indolent Prostate Cancer
Phase: Phase III
Type: Supportive care, Treatment
Status: Active
Age: 50 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: FR-LEU-002, 2012-002653-35, U1111-1146-5402, NCT02085252
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MDV3100-13, NCT02319837
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: NCI, Other
Protocol IDs: PROS0065, NCI-2015-00089, P30CA124435, NCT02346253
Intermittent Hormone Therapy in Men With Localized Prostate Cancer After Radiation Therapy or Radical Prostatectomy
Phase: Phase II
Type: Treatment
Status: Active
Age: over 21
Sponsor: Other
Protocol IDs: 30296-A, L-8863, 06-2040-A-02, NCT00223665
Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation
Phase: Phase II
Type: Treatment
Status: Active
Age: 9 to 40
Sponsor: NCI
Protocol IDs: 110136, 11-C-0136, NCT01338987
The Role of Androgen Deprivation Treatment (ADT) in Docetaxe-Prednisolone Chemotherapy for Castrate-Resistant Prostatic Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UOSG-AMC-0803, NCT01487902
Abiraterone, Radiotherapy and Short-Term Androgen Deprivation in Unfavorable Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Other
Protocol IDs: Pro00044071, NCT01717053
Finite Androgen Ablation vs. Finite Androgen Ablation in Combination With Abiraterone Acetate and Prednisone
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-0993, NCI-2013-00460, NCT01786265
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR103305, ARN-509-002, NCT01790126
Bevacizumab Plus Paclitaxel Optimization Study With Interventional Maintenance Endocrine Therapy in Advanced or Metastatic ER-positive Human Epidermal Growth Factor Receptor 2(HER2)-Negative Breast Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 20 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: JBCRG-M04, NCT01989780
A Phase II Study of Androgen Deprivation Therapy With or Without PD 0332991 in RB-Positive Metastatic Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCC 2013.117, HUM00082715, NCT02059213
Enzalutamide and Hormone Therapy Before, During, and After Radiation for High Risk Localized Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 082013-032, NCT02064582
Multidisciplinary Study of Androgen Deprivation Therapy (ADT) in Prostate Cancer
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 135513, NCT02168062
Phase II Study of Subcutaneous Injection Depot of Leuprolide Acetate in Patient With Prostate Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 40 to 85
Sponsor: Pharmaceutical / Industry
Protocol IDs: HS-12-460, NCT02212197
Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR103352, 212082PCR2036, NCT02217566
Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer - Protocol 2
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 70
Sponsor: Other
Protocol IDs: FASTR-2, NCT02229734
Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 14-283, NCT02268175
Start Over